These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 1735171

  • 1. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ, Vlasuk GP.
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [Abstract] [Full Text] [Related]

  • 2. Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition.
    Lynch JJ, Sitko GR, Mellott MJ, Nutt EM, Lehman ED, Friedman PA, Dunwiddie CT, Vlasuk GP.
    Cardiovasc Res; 1994 Jan; 28(1):78-85. PubMed ID: 8111795
    [Abstract] [Full Text] [Related]

  • 3. Acceleration of recombinant tissue-type plasminogen activator-induced thrombolysis and prevention of reocclusion by the combination of heparin and the Arg-Gly-Asp-containing peptide bitistatin in a canine model of coronary thrombosis.
    Shebuski RJ, Stabilito IJ, Sitko GR, Polokoff MH.
    Circulation; 1990 Jul; 82(1):169-77. PubMed ID: 2114233
    [Abstract] [Full Text] [Related]

  • 4. Acceleration of recombinant tissue-type plasminogen activator-induced reperfusion and prevention of reocclusion by recombinant antistasin, a selective factor Xa inhibitor, in a canine model of femoral arterial thrombosis.
    Mellott MJ, Holahan MA, Lynch JJ, Vlasuk GP, Dunwiddie CT.
    Circ Res; 1992 Jun; 70(6):1152-60. PubMed ID: 1576736
    [Abstract] [Full Text] [Related]

  • 5. Primary prevention of coronary arterial thrombosis with the factor Xa inhibitor rTAP in a canine electrolytic injury model.
    Lynch JJ, Sitko GR, Lehman ED, Vlasuk GP.
    Thromb Haemost; 1995 Aug; 74(2):640-5. PubMed ID: 8585000
    [Abstract] [Full Text] [Related]

  • 6. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ, Kasiewski CJ, Bostwick JS, Bentley R, McVey MJ, White FJ, Perrone MH, Dunwiddie CT.
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [Abstract] [Full Text] [Related]

  • 7. Synergistic combinations of recombinant human tissue-type plasminogen activator and human single-chain urokinase-type plasminogen activator. Effect on thrombolysis and reocclusion in a canine coronary artery thrombosis model with high-grade stenosis.
    Ziskind AA, Gold HK, Yasuda T, Kanke M, Guerrero JL, Fallon JT, Saito T, Collen D.
    Circulation; 1989 Feb; 79(2):393-9. PubMed ID: 2492455
    [Abstract] [Full Text] [Related]

  • 8. A novel synthetic inhibitor of factor Xa decreases early reocclusion and improves 24-h patency after coronary fibrinolysis in dogs.
    Abendschein DR, Baum PK, Verhallen P, Eisenberg PR, Sullivan ME, Light DR.
    J Pharmacol Exp Ther; 2001 Feb; 296(2):567-72. PubMed ID: 11160645
    [Abstract] [Full Text] [Related]

  • 9. Selective inhibition of factor Xa during thrombolytic therapy markedly improves coronary artery patency in a canine model of coronary thrombosis.
    Nicolini FA, Lee P, Malycky JL, Lefkovits J, Kottke-Marchant K, Plow EF, Topol EJ.
    Blood Coagul Fibrinolysis; 1996 Jan; 7(1):39-48. PubMed ID: 8845461
    [Abstract] [Full Text] [Related]

  • 10. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation.
    Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D.
    Circulation; 1991 Mar; 83(3):1038-47. PubMed ID: 1900221
    [Abstract] [Full Text] [Related]

  • 11. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion.
    Haskel EJ, Prager NA, Sobel BE, Abendschein DR.
    Circulation; 1991 Mar; 83(3):1048-56. PubMed ID: 1900222
    [Abstract] [Full Text] [Related]

  • 12. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA, Lee P, Rios G, Kottke-Marchant K, Topol EJ.
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [Abstract] [Full Text] [Related]

  • 13. Combination of inhibition of thrombin and blockade of thromboxane A2 synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries.
    Yao SK, Ober JC, Ferguson JJ, Anderson HV, Maraganore J, Buja LM, Willerson JT.
    Circulation; 1992 Dec; 86(6):1993-9. PubMed ID: 1451271
    [Abstract] [Full Text] [Related]

  • 14. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis.
    Schaffer LW, Davidson JT, Vlasuk GP, Siegl PK.
    Circulation; 1991 Oct; 84(4):1741-8. PubMed ID: 1833089
    [Abstract] [Full Text] [Related]

  • 15. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.
    Rübsamen K, Hornberger W.
    Thromb Haemost; 1996 Jul; 76(1):105-10. PubMed ID: 8819261
    [Abstract] [Full Text] [Related]

  • 16. Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator.
    Saitoh S, Saito T, Otake A, Owada T, Mitsugi M, Hashimoto H, Maruyama Y.
    Arterioscler Thromb; 1993 Apr; 13(4):563-70. PubMed ID: 8385480
    [Abstract] [Full Text] [Related]

  • 17. Thrombin inhibition enhances tissue-type plasminogen activator-induced thrombolysis and delays reocclusion.
    Yao SK, McNatt J, Anderson HV, Eidt J, Cui KX, Golino P, Glas-Greenwalt P, Maraganore J, Buja LM, Willerson JT.
    Am J Physiol; 1992 Feb; 262(2 Pt 2):H374-9. PubMed ID: 1539695
    [Abstract] [Full Text] [Related]

  • 18. Antithrombotic efficacy of a novel factor Xa inhibitor, FXV673, in a canine model of coronary artery thrombolysis.
    Rebello SS, Bentley RG, Morgan SR, Kasiewski CJ, Chu V, Perrone MH, Leadley RJ.
    Br J Pharmacol; 2001 Aug; 133(7):1190-8. PubMed ID: 11487531
    [Abstract] [Full Text] [Related]

  • 19. Oxygen radical scavenging agents as adjuvant therapy with tissue plasminogen activator in a canine model of coronary thrombolysis.
    Przyklenk K, Kloner RA.
    Cardiovasc Res; 1993 Jun; 27(6):925-34. PubMed ID: 8221780
    [Abstract] [Full Text] [Related]

  • 20. Prevention of reocclusion by MCI-9038, a thrombin inhibitor, following t-PA-induced thrombolysis in a canine model of femoral arterial thrombosis.
    Mellott MJ, Connolly TM, York SJ, Bush LR.
    Thromb Haemost; 1990 Dec 28; 64(4):526-34. PubMed ID: 2128137
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.